Erin Sweet


Erin Sweet

Bastyr University Research Institute

School of Naturopathic Medicine



Naturopathic Medicine

Dr. Erin Sweet is an associate research scientist at the Bastyr University Research Institute in Seattle, WA that focuses on integrative oncology.


Dr. Sweet is an associate research scientist at BURI studying the effects of integrative oncology on health-related quality of life and clinical outcomes in people living with cancer. Her goal is to continue working toward a greater understanding and acceptance of integrative medicine using research as a tool. Dr. Sweet is one of fourteen naturopathic physicians in Washington with board certification in naturopathic oncology. 


  • NIH Postdoctoral Research Fellowship at Bastyr University Research Institute (BURI), Seattle, WA.
  • Master of Public Health in Epidemiology from the University of Washington School of Public Health, Seattle, WA.
  • First-Year ND Residency, National University of Natural Medicine, Portland, OR.
  • Doctorate in Naturopathic Medicine from Bastyr University, Seattle, WA.

Professional affiliations

  • American Society of Clinical Oncology
  • Naturopathic Physicians Research Institute
  • Oncology Association of Naturopathic Physicians
  • RAND Center for Collaborative Research in Complementary and Integrative Health
  • Society for Integrative Oncology
  • Affiliated Physician, Tacoma General Hospital

Research philosophy

My primary research interest is the clinical effectiveness of Integrative Oncology (IO) in cancer care. My goal as a physician-scientist is to develop research projects which evaluate IO as an adjunct to conventional oncology treatment.  Broadly, I hypothesize that integrated medical care provided by specialists in naturopathic oncology and the application of evidence-based treatment protocols will improve overall clinical and patient-reported outcomes. 

Research Interests

  • Integrative Oncology
  • Epidemiology
  • Public Health


  • Quantitative
  • Observational
  • Prospective
  • Matched-comparison
  • Cohort

Research highlights

Breast Cancer Integrative Oncology: Prospective Matched Controlled Outcomes Study Identifier: NCT01366248; The Canadian/US Integrative Oncology Study (CUSIOS) Advanced Integrative Oncology treatment for patients with advanced stage cancer: a prospective outcomes study Identifier: NCT02494037.

Sweet E, Dowd F, Zhou M, Standish LJ, Andersen MR. The Use of Complementary and Alternative Medicine Supplements of Potential Concern during Breast Cancer Chemotherapy. Evid Based Complement Alternat Med. 2016;2016:4382687. doi: 10.1155/2016/4382687. Epub 2016 Jul 26. PubMed PMID: 27528880; PubMed Central PMCID: PMC4977399.; Sweet ES, Standish LJ, Goff BA, Andersen MR.

Adverse events associated with complementary and alternative medicine use in ovarian cancer patients. Integr Cancer Ther. 2013 Nov;12(6):508-16. doi: 10.1177/1534735413485815. Epub 2013 Apr 26. Review. PubMed PMID: 23625025; PubMed Central PMCID: PMC4613776.; Sweet ES.

The Practice of Naturopathic Oncology: Levels of Evidence and Decision-Making. In: Kaczor T, editor. Textbook of Naturopathic Oncology 1 ed. Vancouver, British Columbia: Medicatrix Holdings Ltd.; 2020. Chapter 1.8;Standish LJ, Sweet E, Kim E, Dowd F, McLaughlin R, Chiang P, Dale L, Gaul M, Andersen MR.

Recurrence of Breast Cancer After Primary Treatment: A Matched Comparison Study of Disease-Free Survival in Women Who Do and Do Not Receive Adjunctive Naturopathic Oncology Care. Integr Cancer Ther. 2021 Jan-Dec;20:15347354211058404. doi: 10.1177/15347354211058404. PubMed PMID: 34894812; PubMed Central PMCID: PMC8671681

Pub Med Link: